Whether or not the ACH-3422 monotherapy data are presented at AASLD isn't the point; rather, the point is that the release of the ACH-3422 mono data is not a pivotal event for the HCV arena.
Lots of HCV nukes have shown impressive monotherapy data and ended up failing, as has been discussed ad naueam.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.